NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
NOVARTIS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026
$150.20−0.42 (-0.28%)
Close on Oct 19, 2026
- Market cap
- $287.48B
- P/E (TTM)
- 21.0
- Dividend yield
- –
Share price
+$18.77 (+14.28%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $287.48B
- P/E ratio
- 21.0
- Price to sales
- –
- Price to book
- 6.92
- Dividend yield
- –
- Free cash flow yield
- 6.12%
Fundamentals
- Net income
- $13.98B
- EPS, diluted
- $7.15
- Free cash flow
- $17.60B
- Book value per share
- $21.70
- Diluted shares
- 1.91B
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Gross profit
$42.98B+10.5% YoY
Operating income
$17.64B+21.3% YoY
Net income
$13.98B+17.1% YoY
EPS, diluted
$7.15+21.8% YoY
Free cash flow
$17.60B+8.3% YoY
Reported period